Observational study on precision medicine for advanced cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with advanced cancer who are undergoing extensive molecular sequencing as part of a precision oncology program at Charité University Medicine in Berlin. Participants will be registered and monitored to evaluate the effectiveness of individualized therapies and the clinical relevance of identified molecular alterations. The study aims to gather data on the frequency of these alterations and the utility of novel molecular analysis tools in guiding treatment decisions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* advanced cancer
* ability to give written informed consent
* performance status allows initiation of a potential targeted treatment after molecular analysis
* molecular analysis has been done or planned

Exclusion Criteria:

\- unable to give written informed consent

Where it's running

• Charité Comprehensive Cancer Center
  Berlin, Germany Recruiting

Study contacts

• Study coordinator: Damian T Rieke, MD
• Email: cccc@charite.de
• Phone: +49 (0)30 450 564 222

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How to talk about vaccines: does different communication help people decide to get vaccinated?

  This online randomized trial tests whether specific communication formats can improve knowledge and willingness to get vaccinated for TBE (Germany) or yellow fever (Colombia).

  Recruiting Charite University, Berlin, Germany · Berlin, State of Berlin · NCT07921121

• AI-generated treatment recommendations for precision oncology

  A non-interventional study tests whether AI-generated treatment options for advanced solid tumors align with what doctors would personally recommend.

  Recruiting Charite University, Berlin, Germany · Berlin · NCT07897110

• DHEA add-on to standard antidepressants for treatment-resistant depression

  This trial tests whether adding 100 mg/day of DHEA to patients’ current antidepressant treatment helps people with treatment-resistant depression feel better.

  Recruiting at 9 sites Phase 3 Charite University, Berlin, Germany · Berlin, State of Berlin and 8 other locations · NCT07843927

• Context-adapted quality indicators for early sepsis care in Sub-Saharan Africa

  A group of sepsis experts in Sub-Saharan Africa will participate in a series of online surveys and feedback meetings to agree on practical quality indicators for early sepsis care.

  Recruiting Charite University, Berlin, Germany · Kumasi · NCT07711535

• TNPO2-related disorders registry

  This international registry tests how TNPO2 gene variants relate to neurodevelopmental issues by collecting medical, genetic, and developmental data from people with pathogenic TNPO2 variants.

  Recruiting Charite University, Berlin, Germany · Berlin, State of Berlin · NCT07699510

• International TRPM3 Disorder Registry

  This registry tests how TRPM3-associated disorders progress by collecting and comparing patient data over time to learn about treatments and quality of life.

  Recruiting Charite University, Berlin, Germany · Berlin, State of Berlin · NCT07690111

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.